A Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety and Tolerability of SAF312 in Subjects With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Who Are Inadequately Managed by Antimuscarinic Therapy

Trial Profile

A Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety and Tolerability of SAF312 in Subjects With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Who Are Inadequately Managed by Antimuscarinic Therapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs SAF 312 (Primary)
  • Indications Neurogenic bladder; Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 19 Mar 2013 Actual end date changed from Dec 2012 to Sep 2012, as reported by ClinicalTrials.gov.
    • 01 Dec 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 May 2012 Additional location (Belgium) added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top